应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06660 艾美疫苗
休市中 05-03 16:09:00
8.880
+0.160
+1.83%
最高
8.880
最低
8.720
成交量
800.00
今开
8.720
昨收
8.720
日振幅
1.83%
总市值
107.54亿
流通市值
43.71亿
总股本
12.11亿
成交额
7,072
换手率
0.00%
流通股本
4.92亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
艾美疫苗盘中异动 股价大涨5.21%报8.881港元
自选股智能写手 · 05-02 11:22
艾美疫苗盘中异动 股价大涨5.21%报8.881港元
艾美疫苗(06660.HK)主席再增持H股 累计金额1,042万元
阿斯达克财经 · 04-19
艾美疫苗(06660.HK)主席再增持H股 累计金额1,042万元
艾美疫苗(06660)获控股股东周延持续增持股份
智通财经 · 04-18
艾美疫苗(06660)获控股股东周延持续增持股份
艾美疫苗(06660)股价上升5.079%,现价港币$8.69
阿斯达克财经 · 04-18
艾美疫苗(06660)股价上升5.079%,现价港币$8.69
艾美疫苗盘中异动 大幅拉升6.38%
自选股智能写手 · 04-05
艾美疫苗盘中异动 大幅拉升6.38%
艾美疫苗盘中异动 临近收盘急速上涨5.01%
自选股智能写手 · 04-03
艾美疫苗盘中异动 临近收盘急速上涨5.01%
艾美疫苗(06660)上涨5.01%,报8.6元/股
金融界 · 04-03
艾美疫苗(06660)上涨5.01%,报8.6元/股
港股公告掘金 | 联想控股(03396)2023年度实现营收4360.12亿元 个人电脑业务蝉联全球冠军
智通财经 · 04-01
港股公告掘金 | 联想控股(03396)2023年度实现营收4360.12亿元 个人电脑业务蝉联全球冠军
艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市
经济参考网 · 03-28
艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市
艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请
阿斯达克财经 · 03-28
艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请
《公司业绩》艾美疫苗(06660.HK)全年亏损扩至13.01亿人币
阿斯达克财经 · 03-28
《公司业绩》艾美疫苗(06660.HK)全年亏损扩至13.01亿人币
艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市
和讯网 · 03-28
艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市
艾美疫苗10款重磅迭代升级疫苗年内密集申报 其中3款申报上市
南方财经网 · 03-28
艾美疫苗10款重磅迭代升级疫苗年内密集申报 其中3款申报上市
艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开
格隆汇资讯 · 03-28
艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开
艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请
智通财经 · 03-28
艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请
艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请
智通财经 · 03-28
艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请
艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗
智通财经 · 03-28
艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗
狂苗大厂又一重磅迭代升级狂犬疫苗提交临床试验预申请 艾美疫苗(06660)进入密集申报大年
智通财经 · 03-27
狂苗大厂又一重磅迭代升级狂犬疫苗提交临床试验预申请 艾美疫苗(06660)进入密集申报大年
艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请
智通财经 · 03-26
艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请
艾美疫苗(06660)上涨5.04%,报8.96元/股
金融界 · 03-21
艾美疫苗(06660)上涨5.04%,报8.96元/股
暂无数据
公司概况
公司名称:
艾美疫苗
所属市场:
SEHK
上市日期:
--
主营业务:
艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸(mRNA)新冠(COVID-19)疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"06660","market":"HK","secType":"STK","nameCN":"艾美疫苗","latestPrice":8.88,"timestamp":1714723740034,"preClose":8.72,"halted":0,"volume":800,"delay":0,"floatShares":492173711,"shares":1211062599,"eps":-1.1692954,"marketStatus":"休市中","marketStatusCode":7,"change":0.16,"latestTime":"05-03 16:09:00","open":8.72,"high":8.88,"low":8.72,"amount":7072,"amplitude":0.018349,"askPrice":8.9,"askSize":5000,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.1692954387162802,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1664985600000,"adjPreClose":8.72,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.004178854994604859,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06660/tweets","defaultTab":"tweets","newsList":[{"id":"2432690164","title":"艾美疫苗盘中异动 股价大涨5.21%报8.881港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432690164","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432690164?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:22","pubTimestamp":1714620149,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘11时22分,艾美疫苗股票出现波动,股价急速上涨5.21%。截至发稿,该股报8.881港元/股,成交量2万股,换手率0.00%,振幅5.33%。资金方面,该股资金流入14.1486万港元,流出2.0296万港元。机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。艾美疫苗股票所在的药品行业中,整体涨幅为0.46%。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021122297925ab84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021122297925ab84&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428517307","title":"艾美疫苗(06660.HK)主席再增持H股 累计金额1,042万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428517307","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428517307?lang=zh_cn&edition=full","pubTime":"2024-04-19 01:10","pubTimestamp":1713460200,"startTime":"0","endTime":"0","summary":"艾美疫苗(06660.HK) 公布,1月12日至本月15日期间,主席、首席执行官及控股股东周延通过公开市场进一步增持公司H股。自去年11月14日至本月15日,周氏已通过公开市场以自有资金1,042万元持续增持公司H股。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-18 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20221108125356747_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20221108125356747_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343412/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428560260","title":"艾美疫苗(06660)获控股股东周延持续增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2428560260","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428560260?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:51","pubTimestamp":1713441062,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 发布公告,公司董事会收到周延通知,周延于2024年1月12日至2024年4月15日期间通过公开市场进一步持续增持公司H股股份。自2023年11月14日至2024年4月15日,周延已通过公开市场以自有资金合计10,420,212.00港元持续增持公司H股股份,且不排除会在适当时候继续增持公司股份。在本次增持后及于本公告日期,公司仍满足上市规则第8.08条规定的充足公众持股量的要求。本次增持也并未导致公司控制权发生变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104803.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428358829","title":"艾美疫苗(06660)股价上升5.079%,现价港币$8.69","url":"https://stock-news.laohu8.com/highlight/detail?id=2428358829","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428358829?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:35","pubTimestamp":1713404100,"startTime":"0","endTime":"0","summary":"[上升股]艾美疫苗(06660) 股价在上午09:35比前收市价上升5.079%,现股价为港币$8.69。至目前为止,今日最高价为$8.69,而最低价为$8.69。总成交量为200股,总成交金额为港币$1738。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240418146/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2425437737","title":"艾美疫苗盘中异动 大幅拉升6.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425437737","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425437737?lang=zh_cn&edition=full","pubTime":"2024-04-05 09:31","pubTimestamp":1712280682,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘09时31分,艾美疫苗股票出现波动,股价快速拉升6.38%。艾美疫苗股票所在的药品行业中,整体涨幅为0.15%。其相关个股中,三爱健康集团、艾美疫苗、中智药业涨幅较大,振幅较大的相关个股有三爱健康集团、兆科眼科-B、中国生物制药,振幅分别为5.41%、3.77%、3.42%。随着2024年多款重磅大单品疫苗的陆续上市,艾美疫苗在中国市场的领先地位将进一步巩固。未来艾美疫苗这两个大单品疫苗的上市,将成为公司业绩增长的爆发点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050931237a510bfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050931237a510bfb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424864496","title":"艾美疫苗盘中异动 临近收盘急速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424864496","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424864496?lang=zh_cn&edition=full","pubTime":"2024-04-03 15:46","pubTimestamp":1712130418,"startTime":"0","endTime":"0","summary":"2024年04月03日临近收盘15时46分,艾美疫苗股票出现异动,股价大幅上涨5.01%。艾美疫苗股票所在的药品行业中,整体跌幅为0.14%。其相关个股中,艾美疫苗、凯莱英、东阳光长江药业涨幅较大,振幅较大的相关个股有三爱健康集团、泰凌医药、中生联合,振幅分别为17.50%、13.64%、8.33%。年报显示,截至2023年年底,艾美疫苗取得了14个临床批件,开展了21项临床试验,其中5个已处于III期临床收尾阶段,正在开展上市前的各项准备工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031546587a50e3c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031546587a50e3c1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424586404","title":"艾美疫苗(06660)上涨5.01%,报8.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424586404","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424586404?lang=zh_cn&edition=full","pubTime":"2024-04-03 15:46","pubTimestamp":1712130418,"startTime":"0","endTime":"0","summary":"4月3日,艾美疫苗(06660)盘中上涨5.01%,截至15:46,报8.6元/股,成交230.34万元。艾美疫苗股份有限公司是中国第二大疫苗供应商,涵盖了从研发到制造、再到商业化的整个价值链,并在全球范围内拥有五种经过验证的人用疫苗平台技术。2021年销售收入市场份额为2.1%,批签发量在所有民营疫苗公司中处于领先地位,同时也是中国首批获得P3实验室建设许可的疫苗企业之一。截至2023年年报,艾美疫苗营业总收入11.87亿元、净利润-13.01亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/03154640114857.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424167297","title":"港股公告掘金 | 联想控股(03396)2023年度实现营收4360.12亿元 个人电脑业务蝉联全球冠军","url":"https://stock-news.laohu8.com/highlight/detail?id=2424167297","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424167297?lang=zh_cn&edition=full","pubTime":"2024-04-01 20:09","pubTimestamp":1711973379,"startTime":"0","endTime":"0","summary":"【重大事项】广汽集团(02238)拟在A股和H股以集中竞价交易方式回购公司股份中国光大银行(06818)获控股股东光大集团增持6432.14万股A股股份 拟累计增持4亿元-8亿元艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗赛生药业(06600)获Silver Pegasus 溢价约17.21%提私有化 4月2日复牌国际资源(01051)附属拟2500万美元认购一项基金的","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1097304.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422135485","title":"艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422135485","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2422135485?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:32","pubTimestamp":1711607520,"startTime":"0","endTime":"0","summary":"13价肺炎结合疫苗、无血清迭代狂犬疫苗、23价肺炎多糖疫苗等3款迭代升级产品,预计在2024年内申报上市。年报显示,艾美疫苗2023年业绩亏损,主要原因是受新冠疫情变化影响,公司计提无形资产和商誉减值。2024年,艾美疫苗有3款疫苗申报上市,7款疫苗申报临床,公司产品已打开国际市场大门,出海步伐正在加速。高效研发彰显创新底气在业绩公告发布的同时,艾美疫苗还公告了多款迭代升级疫苗的研发进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281436298b6c9019&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281436298b6c9019&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422049609","title":"艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422049609","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422049609?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:28","pubTimestamp":1711592880,"startTime":"0","endTime":"0","summary":"艾美疫苗(06660.HK) 公布,已于昨日(27日)提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请,且已于2月9日提交吸附破伤风疫苗的临床试验预申请。上述两款疫苗的研发符合公司产品研发战略布局,是实现公司研发多联多价产品的重要一步,将进一步完善公司的产品梯队。此外,集团已于昨日提交四价MDCK细胞流感病毒疫苗的临床试验预申请。目前,国内上市的流感疫苗均基于鸡胚工艺生产,尚无基于细胞基质的流感疫苗获批上市。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220923085721595_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220923085721595_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338153/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422904425","title":"《公司业绩》艾美疫苗(06660.HK)全年亏损扩至13.01亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2422904425","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422904425?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:17","pubTimestamp":1711592220,"startTime":"0","endTime":"0","summary":"艾美疫苗(06660.HK) 公布截至去年12月底止全年业绩,营业额11.87亿元人民币(下同),按年跌6.1%。亏损扩大至13.01亿元,上年同期蚀3.2亿元;每股亏损1.07元。不派息。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)过往派息公布日期派息事项派息内容2023/08/29中期业绩无派息2023/03/29末期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200103175221798_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200103175221798_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338149/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422390479","title":"艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422390479","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2422390479?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:13","pubTimestamp":1711588425,"startTime":"0","endTime":"0","summary":"快讯正文艾美疫苗进入密集申报大年,mRNA技术平台布局多个爆款疫苗艾美疫苗近日发布2023年业绩及多个重磅新品研发公告。据公告显示,该公司2023年研发费用超过6.36亿元,同比增长27.2%,并有多款疫苗产品即将申报上市。根据年报数据,艾美疫苗已获得14个临床批件,并开展了21项临床试验。艾美疫苗目前已经商业化八款疫苗产品,其中,汉逊酵母重组乙型肝炎疫苗及Vero细胞冻干人用狂犬病疫苗在市场上处于领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281036248b6bb544&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281036248b6bb544&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422977273","title":"艾美疫苗10款重磅迭代升级疫苗年内密集申报 其中3款申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422977273","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422977273?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:55","pubTimestamp":1711587327,"startTime":"0","endTime":"0","summary":"南方财经3月28日电,艾美疫苗今日公告2023年业绩,期内研发费用超6.36亿元,同比增长27.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283027141819.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422839977","title":"艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2422839977","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422839977?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:24","pubTimestamp":1711585469,"startTime":"0","endTime":"0","summary":"艾美疫苗今日公布2023财年业绩报告,期内研发费用超6.36亿元,同比增长27.2%,今年3款重磅迭代升级疫苗申报上市,7款申报临床。截至2023年底,艾美取得了14个临床批件,开展了21项临床试验,5个处于III期临床收尾阶段。目前,13价肺炎结合疫苗、无血清迭代狂犬疫苗、23价肺炎多糖疫苗等3款重磅迭代升级疫苗,今年完成上市申报,有望尽快为公司业绩带来大幅增长。公司已上市的甲肝疫苗、乙肝疫苗和狂犬疫苗都是国际市场青睐的品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280838188b6b7059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280838188b6b7059&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422971118","title":"艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422971118","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422971118?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:13","pubTimestamp":1711584787,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 发布公告,该集团已于2024年3月27日提交四价MDCK细胞流感病毒疫苗的临床试验预申请。目前,国内上市的流感疫苗均基于鸡胚工艺生产,尚无基于细胞基质的流感疫苗获批上市。此外,公司研发的MDCK细胞流感疫苗,在传代过程中病毒突变几率低,不含卵清蛋白,过敏风险显著降低。接种流感疫苗是预防流感疾病及流感大爆发最经济、有效的措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094334.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422971430","title":"艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422971430","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422971430?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:12","pubTimestamp":1711584724,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 公布,该集团已于2024年3月27日提交b型流感嗜血杆菌结合疫苗的临床试验预申请,且已于2024年2月9日提交吸附破伤风疫苗的临床试验预申请。此外,集团正在积极推进吸附无细胞百白破b型流感嗜血杆菌联合疫苗的研发,预计从2024年开始会陆续提交多联疫苗及其各组分疫苗的临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094335.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422979068","title":"艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2422979068","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422979068?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:04","pubTimestamp":1711584253,"startTime":"0","endTime":"0","summary":"艾美疫苗目前已经商业化八款疫苗产品,其中,汉逊酵母重组乙型肝炎疫苗及Vero细胞冻干人用狂犬病疫苗在市场上处于领先地位。值得关注的是,公司布局的mRNA疫苗技术平台及产品居于行业领先地位,上万例受试者的临床试验数据已充分验证了该平台产品的安全性和有效性,多款热门重磅大单品疫苗已在加速推进。未来,艾美疫苗将在此基础上持续推动mRNA疫苗创新,重点关注核心疾病领域中未被满足的临床需求,进一步提升核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094330.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422916603","title":"狂苗大厂又一重磅迭代升级狂犬疫苗提交临床试验预申请 艾美疫苗(06660)进入密集申报大年","url":"https://stock-news.laohu8.com/highlight/detail?id=2422916603","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422916603?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:44","pubTimestamp":1711500252,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,艾美疫苗26日晚间公告,公司已于日前提交新型工艺高效价人二倍体狂犬病疫苗的临床试验预申请。截至目前,全球市场上尚未有无血清狂犬病疫苗获批上市。艾美疫苗自主创新的mRNA技术平台,已通过上万例受试者临床试验数据的验证,在此平台上开发的mRNA迭代狂犬病疫苗,是国家药品审评中心受理临床试验申请的首款非新冠mRNA疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093076.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422661387","title":"艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422661387","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422661387?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:23","pubTimestamp":1711459436,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 发布公告,集团已于2024年3月24日提交新型工艺高效价人二倍体狂犬病疫苗的临床试验预申请。集团已建设完成具备生产能力且满足国际化标准的新型工艺高效价人二倍体狂犬病疫苗车间,并正在进行设备调试和验证工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092788.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421906192","title":"艾美疫苗(06660)上涨5.04%,报8.96元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421906192","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421906192?lang=zh_cn&edition=full","pubTime":"2024-03-21 15:36","pubTimestamp":1711006614,"startTime":"0","endTime":"0","summary":"3月21日,艾美疫苗(06660)盘中上涨5.04%,截至15:36,报8.96元/股,成交448.32万元。艾美疫苗股份有限公司是中国第二大疫苗供应商,涵盖了从研发到制造、再到商业化的整个价值链,并在全球范围内拥有五种经过验证的人用疫苗平台技术。2021年销售收入市场份额为2.1%,批签发量在所有民营疫苗公司中处于领先地位,同时也是中国首批获得P3实验室建设许可的疫苗企业之一。截至2023年中报,艾美疫苗营业总收入5.4亿元、净利润-2.5亿元。3月27日,艾美疫苗将披露2023财年年报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/21153639938188.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aimbio.com","stockEarnings":[{"period":"1week","weight":0.0764},{"period":"1month","weight":0.0496},{"period":"3month","weight":0.3136},{"period":"6month","weight":-0.0022},{"period":"1year","weight":-0.7906},{"period":"ytd","weight":0.1312}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸(mRNA)新冠(COVID-19)疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"艾美疫苗","nameEN":"AIM VACCINE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾美疫苗,06660,艾美疫苗股票,艾美疫苗股票老虎,艾美疫苗股票老虎国际,艾美疫苗行情,艾美疫苗股票行情,艾美疫苗股价,艾美疫苗股市,艾美疫苗股票价格,艾美疫苗股票交易,艾美疫苗股票购买,艾美疫苗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}